Clinical Trial

Cyclosporine In Takotsubo Syndrome

Study acronym: CIT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to investigate the impact of repetitive acute Cyclosporine A (CsA) bolus therapy in patients suffering from TTS with an elevated risk of impaired outcome. The main question it aims to answer is whether CsA reduces myocardial injury (primary outcome). Participants will receive CsA or placebo at baseline and every 12h in the first 24h after study inclusion. Researchers will compare CsA and the placebo group to see if a) myocardial injury is reduced, and b) ejection fraction is improved compared to baseline, as well as several other secondary endpoints over a one year follow-up.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-07-07; most recent amendment 2026-04-27.
Status change: Not Yet Recruiting → Recruiting 2025-04-04
Trial Details
NCT Number NCT05946772
Lead Sponsor University Hospital Heidelberg
Collaborators: German Centre of Cardiovascular Research (DZHK), Coordinating Centre for Clinical Studies (KKS) Heidelberg
Conditions Takotsubo Cardiomyopathy
Enrollment 204 participants
Start Date 2025-02-01
Primary Completion 2027-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-05-01